Markets Earnings Screener Watchlist

Fundamentals and filings are sourced from SEC EDGAR. Market data, ownership and analyst consensus are sourced from Nasdaq. Written analysis is generated by metir from those sources and the linked reporting.

All information is provided for informational purposes only. It is not investment, financial, tax or legal advice, is not a recommendation to buy or sell any security, and is not intended for trading purposes. Data may be delayed or incomplete.

Markets open

Royalty Pharma plc Class A Ordinary Shares Stock Price: Quote, Financials, Forecast & News (RPRX)

Royalty Pharma plc Class A Ordinary Shares

RPRX · Nasdaq

Overview Financials Earnings Holders Historical Data Analysis

$58.04+$0.560.97%

As of: Aug 5, 2:39 PM

Prev Close: $57.48
Market Cap: $33.42B
Open: —
Trailing P/E: —
Day Range: $59.63 - $57.90
52W Range: $60.44 - $34.08
Forward P/E: —
EPS: —
Volume: 605.55K
Dividend Yield: 1.64%

Notable Price Movement

Weekly movement commentary will appear here once it has been generated for this company.

Stories & Analysis

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Zacks · 5h ago

Royalty Pharma Q2 Net Income Declines; Raises 2026 Guidance For Portfolio Receipts

RTTNews · 6h ago

Royalty Pharma Q2 26 Earnings Conference Call At 8:00 AM ET

RTTNews · 7h ago

Gear Up for Royalty Pharma (RPRX) Q2 Earnings: Wall Street Estimates for Key Metrics

Zacks · 1d ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks · 2d ago iShares US Pharmaceuticals ETF Experiences Big Inflow

BNK Invest · 5d ago Will Iovance Biotherapeutics (IOVA) Report Negative Q2 Earnings? What You Should Know

Zacks · 6d ago How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Zacks · 6d ago

Symbol: RPRX
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: Nasdaq

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators.

Analyst Consensus

Buy

7 analysts

$58

Current

—

Low

$62

Average

—

High

Average target implies +6.82% versus the current price.

Earnings History

BeatMissNo estimate

Peers

BeOne Medicines Ltd. American Depositary SharesONC · Nasdaq$332.352.89%
Waters CorporationWAT · NYSE$394.450.41%
IQVIA Holdings, Inc.IQV · NYSE$235.453.18%
Agilent Technologies, Inc.A · NYSE$140.390.85%

Beta

—

Avg Volume

3.54M